Madrigal Pharmaceuticals, Inc.

MDGL

NASDAQ

Healthcare

Biotechnology

West Conshohocken, PA, US528 employeesmadrigalpharma.com

$544.43

+14.59(2.75%)

Mkt Cap $12.5B

$267.56

$602.83

52-Week Range

At a Glance

AI-generated

Madrigal Pharmaceuticals, Inc.

Revenue breakdown: Reportable Segment (100%).

8-K

Madrigal Pharmaceuticals, Inc. issued a press release on February 19, 2026, announcing results of operations and financial condition. The filing includes Exhibit 99.1, the press release dated February 19, 2026.

$12.5B

Market Cap

$980M

Revenue

-$295M

Net Income

Employees528

Fundamentals

How The Business Makes Money

Revenue by Segment

Reportable Segment100%($1.1B)

Activity

What Changed Recently

Financial Results

Feb 18, 2026

Results of Operations and Financial Condition. On February 19, 2026, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Compan

Material Agreement

Jan 29, 2026

Entry into a Material Definitive Agreement. On January 29, 2026 (the “Effective Date”), Madrigal Pharmaceuticals, Inc. (the “Company”), F. Hoffmann-La Roche Ltd

Peer Companies

Company	Price	Change	Market Cap	P/E
MRNAModerna, Inc.	$49.11	-1.84%	$19.4B	-7.1
EXELExelixis, Inc.	$43.87	-0.39%	$11.8B	14.4
JAZZJazz Pharmaceuticals plc	$186.84	-0.76%	$11.5B	-31.2
BMRNBioMarin Pharmaceutical I...	$55.51	-3.03%	$10.7B	30.1
BAXBaxter International Inc.	$16.69	-0.54%	$8.6B	-8.9
TECHBio-Techne Corporation	$53.13	-0.66%	$8.3B	99.9
ABVXAbivax S.A.	$118.21	+2.82%	$7.8B	-33.0
RYTMRhythm Pharmaceuticals, I...	$86.33	-2.04%	$5.9B	-28.8

Analyst View

Company Profile

CIK0001157601

ISINUS5588681057

CUSIP558868105

Phone267 824 2827

AddressFour Tower Bridge, West Conshohocken, PA, 19428, US

SEC EDGAR